Biotech Startups funded by Y Combinator (YC) 2024

April 2024

Browse 100 of the top Biotech startups funded by Y Combinator.

We also have a Startup Directory where you can search through over 5,000 companies.

  • Notable Labs
    Notable Labs (w2015)Public • 40 employees • Foster City, CA, USA
    Notable Labs is building a personalized drug discovery platform to identify treatment options for relapsed and refractory cancer patients — starting with blood cancer — to address the long tail of cancer treatment. We look at a person’s actual cancer cells, test combinations of FDA approved drugs, and see which combinations kill the cancer cells and leave the healthy cells alive. We focus on combinations because cancer is often difficult to target with just one drug and starting with a single drug can lead to resistant clones or relapse. We're building a highly automated lab in Foster City running on our custom software and are currently testing relapsed/refractory cancer patients as well as samples from a variety of pharma/biotech partnerships. https://www.notablelabs.com/careers
    biotech
    drug-discovery
    oncology
  • Pardes Biosciences
    Pardes Biosciences (s2020)Public • 2 employees • San Francisco, CA, USA
    We make oral drugs to treat and prevent viral infections - like COVID-19.
    biotech
    therapeutics
  • Benchling
    Benchling (s2012)Active • 750 employees • San Francisco, CA, USA
    Biotechnology is rewriting life as we know it, from the medicines we take, to the crops we grow, the materials we wear, and the household goods that we rely on every day. Biotech R&D is radically transforming our world, but to move at the new speed of science, scientists need better technology. Benchling’s mission is to unlock the power of biotechnology. The world’s biotech leaders and innovators use our R&D Cloud to power the development of breakthrough products and accelerate time to milestone and market.
    saas
    b2b
    biotech
  • Opentrons
    Opentrons (w2016)Active • 300 employees • New York, NY, USA
    Today, biologists spend too much time pipetting by hand. We think biologists should have robots to do pipetting for them. People doing science should be free of tedious benchwork and repetitive stress injuries. They should be able to spend their time designing experiments and analyzing data. That's why we started Opentrons. We make robots for biologists. Our mission is to provide the scientific community with a common platform to easily share protocols and reproduce each other's results. Our robots automate experiments that would otherwise be done by hand, allowing our community to spend more time pursuing answers to some of the 21st century’s most important questions.
    robotics
    synthetic-biology
    biotech
  • Athelas
    Athelas (s2016)Active • 160 employees • Mountain View, CA, USA
    At Athelas, we're bringing simple, life-changing health care products to people around the globe. The future of healthcare is at the home - we are a team of technologists building the next generation of medical products at the intersection of hardware and software. We won’t stop until we’ve brought the world class tools of a hospital to your home. Athelas Remote Patient Monitoring (RPM) allows healthcare providers to monitor patient vitals like blood pressure, weight, and blood glucose without the patient ever having to enter a clinic, improving patient health and engagement, and reducing hospitalizations. We do this all through a beautifully integrated suite of devices and software tools that provides access to state-of-the-art technologies and groundbreaking AI powered analysis.
    health-tech
    medical-devices
    biotech
    healthcare
  • Atomwise
    Atomwise (w2015)Active • 67 employees • San Francisco, CA, USA
    Atomwise is a preclinical tech-enabled biotech using machine learning for hit discovery, hit expansion, and lead optimization. We were the first team to apply convolutional neural networks to drug discovery. We focus on identifying and optimizing novel small molecule scaffolds and unlocking previously-undrugged protein targets.
    ai-powered-drug-discovery
    deep-learning
    biotech
    drug-discovery
    oncology
  • Asher Bio
    Asher Bio (s2019)Active • 3 employees • San Carlos, CA, USA
    Asher Bio is a biotechnology company developing precisely targeted immunotherapies for cancer and other diseases. Our cis-targeting platform aims to enable selective activation of specific immune cell types, addressing the inherent limitations of otherwise pleiotropic immunotherapies that act on multiple cell types. Our approach has the potential to precisely direct different immune mediators against a range of target immune cell-types and create best-in-class immunotherapies in cancer, autoimmune and infectious diseases. Asher Bio is backed by Third Rock Ventures and is located in South San Francisco.
    biotech
  • Culture Biosciences
    Culture Biosciences (w2018)Active • 40 employees • South San Francisco, CA, USA
    Culture Biosciences grows cells for biotech companies. Our customers genetically modify organisms to produce new therapeutics, materials, fuels and foods. We help them quickly run experiments and develop manufacturing processes so they can get their products to market faster. We've built proprietary software and automation systems to make operating our bioreactors more efficient than existing systems. We also provide customers with new software tools that help them analyze and contextualize their data. We are currently serving a number of biotech customers and scaling out our infrastructure.
    cellular-agriculture
    biotech
  • Verge Genomics
    Verge Genomics (s2015)Active • 50 employees • San Francisco, CA, USA
    Verge uses artificial intelligence and human data to develop better drugs faster. Verge has an end-to-end technology-driven drug discovery and development platform, featuring one of the field’s largest and most comprehensive proprietary patient genomics datasets from human tissue. Verge uses machine learning to mine this data and develops these insights into new drugs using it’s human-centric biology and chemistry platforms.
    ai-powered-drug-discovery
    biotech
    healthcare
  • Ansa Biotechnologies
    Ansa Biotechnologies (w2020)Active • 72 employees • Emeryville, CA, USA
    Ansa Biotechnologies is developing a new way to make DNA that will be faster, cleaner, and more accurate than existing methods. Currently, DNA is manufactured via a chemical method that has remained mostly unchanged for 35 years. Our enzyme-based approach promises to dramatically accelerate innovation in biological research and biotechnology, including therapeutics, diagnostics and biomanufacturing.
    synthetic-biology
    biotech
  • Science Exchange
    Science Exchange (s2011)Active • 50 employees • Palo Alto, CA, USA
    Science Exchange powers R&D outsourcing for the world’s top life sciences companies. Our marketplace gives scientists access to the innovation and research they need and our platform fully automates R&D outsourcing from source to pay so scientists can focus on what they love—science.
    saas
    health-tech
    biotech
    enterprise
  • Mytos
    Mytos (s2018)Active • 26 employees • London, UK
    Mytos builds machines that automate the growing of human cells for biotech and pharma companies. Our machines sit on-prem at customer sites, growing cells which they use for testing during early-stage drug development. Even though testing on cells is so critical for developing new drugs, today they're all grown totally manually, the same as 100 years ago! With our machines, for the first time our customers can hands-off manipulate and monitor batches of cells from the cloud. We've already working with some of the biggest pharma companies. Mytos has the opportunity to change the way the entire industry works - join us and help us get there!
    biotech
  • Velorum Therapeutics
    Velorum Therapeutics (w2024)Active • 3 employees • San Francisco, CA, USA
    Velorum Therapeutics is developing a new class of cancer drugs that starve tumors by hijacking cancer metabolism. We have shown our drugs work in mice and plan to begin human clinical trials next year, starting with the #1 cancer killer – lung cancer.
    biotech
    healthcare
    therapeutics
    drug-discovery
    oncology
  • Birch Biosciences
    Birch Biosciences (s2022)Active • 8 employees • Portland, OR, USA
    Birch Biosciences engineers enzymes for plastic recycling using synthetic biology and machine learning. Our enzymes function as high performance “molecular scissors” that efficiently break down plastic polymers into chemical building blocks that can be used to manufacture high quality recycled plastic products. Today, plastic manufacturing is unsustainable and a major driver of climate change. Birch Biosciences is developing an economical end-to-end plastic recycling process that reduces carbon emissions by 70% and enables a circular plastic economy.
    machine-learning
    synthetic-biology
    biotech
    climate
    climatetech
  • Ohmic Biosciences
    Ohmic Biosciences (s2023)Active • 2 employees • Alameda, CA, USA
    Pests and pathogens cost the world hundreds of billions of dollars every year. Existing technologies like agrochemicals are no longer working. Ohmic Biosciences uses protein engineering to design resistance genes for crops that are robust to pathogen evolution.
    synthetic-biology
    biotech
    climate
    agriculture
    genetic-engineering
  • Serna Bio
    Serna Bio (w2021)Active • 2 employees • Ontario, CA, USA
    We develop novel therapeutics for globally relevant, diseases of high unmet medical need, by targeting the transcriptome.
    biotech
    drug-discovery
  • Eris Biotech
    Eris Biotech (w2024)Active • 2 employees • American Fork, UT 84003, USA
    We are developing cancer therapeutics using small molecules that inhibit immune suppression. Our drugs engage the immune system to aggressively fight tumors. In addition, our drugs have a unique delivery mechanism known as hypoxia-activated prodrugs (HAPs). HAPs are drugs designed to become active in a hypoxic (low oxygen) environment, which is a hallmark of the majority of solid tumors. By delivering active drugs only to the tumor site, we hope to overcome systemic toxicity in cancer therapeutics. Our therapeutic portfolio addresses a range of solid tumors, starting with mesothelioma.
    biotech
    therapeutics
    drug-discovery
    oncology
  • Trestle Biotherapeutics
    Trestle Biotherapeutics (w2021)Active • 2 employees • San Diego, CA, USA
    We are developing an implantable therapeutic tissue that will be surgically delivered to patients suffering from end stage renal disease. Upon implantation, this tissue will supplement the patient's renal function, eliminating their dependency on dialysis and improving their disease status. This has the potential to not only get these patients off dialysis - a significant impact for them and their families - but to greatly extend the time required before kidney transplantation is essential.
    biotech
  • Junction Bioscience
    Junction Bioscience (w2024)Active • 1 employees • San Francisco, CA, USA
    Junction Bioscience is building an autonomous AI scientist to navigate the discovery of transformative medicines. Our scientific hypothesis engine iterates upon breakthrough chemistry from the laboratory to achieve clarity and control over the molecular basis of disease. We focus on the intersection of neuroinflammation and immunology where uncommon molecular insights position us to develop best-in-class therapies for millions of patients in need.
    ai-powered-drug-discovery
    biotech
    therapeutics
    drug-discovery
    ai
  • Maverick BioMetals
    Maverick BioMetals (s2022)Active • 9 employees • San Antonio, TX, USA
    Maverick BioMetals is a biotechnology company advancing lithium processing. The company was founded by Eric Herrera, former Department of Defense scientist, and Jesse Evans, former startup operations manager. We've developed a biological process to efficiently extract lithium from hard rock deposits. Our custom process is greener, more energy efficient, and cost effective compared to the current methods of extracting lithium. We're currently developing partnerships with mining companies to further the commercialization of our technology.
    biotech
    climate
    genomics
    genetic-engineering
  • Invert
    Invert (w2022)Active • 23 employees • Copenhagen, Denmark
    We build software to manage, analyze, and optimize bioprocessing data. Our initial customers are bio-industrial companies, who produce various products in bioreactors.
    cellular-agriculture
    machine-learning
    synthetic-biology
    biotech
  • Granza Bio
    Granza Bio (w2024)Active • 2 employees • San Francisco, CA, USA
    Granza Bio is developing cancer therapeutics modelled from our body’s own immune system. Our therapeutics termed “attack particles” are engineered to specifically target only cancer cells, preventing any unwanted toxicity and adverse side effects. Our attack particles have shown cancer-killing efficacy in brain (glioblastoma), ovarian, lung, and skin cancers. Our platform can also be deployed to target a great range of diseases including autoimmune diseases and infections. Interested to know more? Get in touch founders@granzabio.com!
    synthetic-biology
    biotech
    healthcare
    therapeutics
    oncology
  • Hepatx
    Hepatx (s2018)Active • 4 employees • Palo Alto, CA, USA
    Our vision is to provide regenerative medicine treatments that free patients from chronic liver disease and help usher in an era where diseased and damaged tissues can be repaired.
    biotech
  • Cleancard
    Cleancard (s2023)Active • 5 employees • San Francisco, CA, USA
    We are combining synthetic biology and artificial intelligence to make cancer screening as easy as a pregnancy test. Cleancard is bringing lab-grade diagnostics into the comfort of your home. Our novel method enables robust diagnostics and biomarker tracking from the urine in just 30 minutes. Our rapid at-home screens can identify prostate, bladder and ovarian cancers. We are constantly expanding the number of conditions we can detect from a single sample using our platform technology.
    computer-vision
    biotech
    healthcare
    diagnostics
    ai
  • Diffuse Bio
    Diffuse Bio (w2023)Active • 5 employees
    At Diffuse Bio we’re building a push-button entirely AI software platform for molecular design, leveraging breakthroughs in generative AI. Our team has been behind breakthroughs in AI protein design for the past 6 years, including the first experimental validation of AI-generated proteins and diffusion models for protein structure and sequence.
    ai-powered-drug-discovery
    deep-learning
    generative-ai
    machine-learning
    biotech
  • Maven Bio
    Maven Bio (s2023)Active • 3 employees • Boston, MA, USA
    The way therapeutic opportunities are often evaluated today is through a heavy dose of consultants, hundreds of slides, and ultimately highly fragmented and incomplete information. We believe this high content, low insight process is a core driver of inefficiency in the industry. Maven is building the platform that will allow stakeholders of all disciplines to effectively evaluate therapeutic opportunities. 169 Drugs each year fail in clinical development due to business and commercial reasons (only ~60 drugs are approved annually). That number represents roughly 20% of all clinical development programs, or roughly $28 billion in sub-optimal R&D dollars annually. At Maven Bio, our goal is to halve the commercial failure rate and thereby increase the number of drugs that are approved and available to patients. To start, Maven is building a biopharma commercial intelligence platform which allows corporate development teams to rapidly construct deal landscapes and conduct comparative analyses. Maven empowers users with evidence-backed insights based on their business context. Over time, Maven will add additional knowledge areas to the platform to provide an increasingly comprehensive and accurate assessment of a therapeutic opportunity.
    generative-ai
    biotech
    healthcare
    enterprise
    healthcare-it
  • Miracle
    Miracle (w2023)Active • 3 employees • San Francisco, CA, USA
    Miracle puts Clinical Operations in control. For biotech/pharma companies, Miracle is the "control room" for clinical trial management. Miracle helps save time by integrating vendor reports and trial data sources (i.e. EDC, IRT, study website) into a unified, real-time dashboard, replacing manual spreadsheet trackers. A number of biotech companies use Miracle today to automate reporting in patient recruitment, data cleaning, drug supply, forecast screenings/randomizations, etc., on their Phase 2 and 3 clinical trials.
    saas
    b2b
    biotech
    healthcare
  • ParcelBio
    ParcelBio (w2024)Active • 3 employees • San Francisco, CA, USA
    ParcelBio is developing a programmable technology to safely and specifically deliver mRNA to diverse cell types in the body. Our proprietary (nanoparticle-free) technology, which we call ‘STAmP’, stabilizes the mRNA and utilizes an interchangeable, lock-and-key-like targeting mechanism which enables fully customizable mRNA medicines.
    gene-therapy
    biotech
    healthcare
    drug-delivery
    therapeutics
  • Probably Genetic
    Probably Genetic (w2019)Active • 9 employees • San Francisco, CA, USA
    Probably Genetic is changing the lives of patients living with severe, complex diseases. Our data platform is used by drug developers and patient advocacy groups to develop and launch treatments for these patients. Our technology discovers undiagnosed patients online, analyzes their disease state using machine learning and at-home testing, and enables compliant communication with patients. In doing so, we help patients access diagnoses, clinical trials, and treatments as early as possible.
    health-tech
    biotech
    genomics
  • Living Carbon
    Living Carbon (w2020)Active • 40 employees • Charleston, SC, USA
    Public benefit company on a mission to fight climate change by genetically enhancing CO2 capture and storage in plants.
    synthetic-biology
    biotech
    climate
    agriculture
  • Shasqi
    Shasqi (w2015)Active • 28 employees • San Francisco, CA, USA
    Shasqi is leading the development of therapeutics leveraging click chemistry to get active cancer treatments to tumors with its proprietary CAPAC™ platform. Our technology is based on localizing a click chemistry reagent in the tumor area, which then activates a second agent, a systemically infused protodrug. When the two 'click', a powerful localized therapy is activated at the tumor, while keeping its systemic exposure levels below toxic thresholds.
    biotech
    therapeutics
  • YourChoice Therapeutics
    YourChoice Therapeutics (w2019)Active • 3 employees • Berkeley, CA, USA
    YourChoice Therapeutics is revolutionizing the global contraceptive market. Our vision is to develop non-hormonal contraceptives to provide both women and men with birth control options that lack the associated risks of hormone-based options but are equally effective. Traditionally, it has been the women’s financial and health burden to have a contraceptive in place. Our first goal is therefore to bring a novel non-hormonal, on-demand and low cost female contraceptive to the market that will substantially improve their quality of life and well-being. Our second goal is to develop the first ever non-surgical and highly effective non-hormonal contraceptive for men. Currently, male contraception is limited to two main options – vasectomy or condoms. Having such options available to both women and men will globally allow for much better family planning, reduce the number of unwanted pregnancies including abortions and therefore reduce costs and ensure contraceptive health and well-being.
    health-tech
    biotech
  • Harmonic Discovery
    Harmonic Discovery (s2021)Active • 8 employees • New York, NY, USA
    We are a drug discovery company developing a new generation of therapeutics that embrace the complexity of disease. Currently available approaches for creating drugs work on the principle of finding one drug-one protein 'magic bullets'. However, diseases such as cancer and autoimmunity are often the result of several dysregulated proteins across many distinct biological pathways. We are building a computational-experimental platform to design therapeutics that can target several disease-causing proteins at once. By designing multi-specific drugs, we are able to create therapeutics that are more efficacious and safer than existing medicines.
    ai-powered-drug-discovery
    biotech
    healthcare
    drug-discovery
  • Immunity Project (w2014)Active • 11 employees • San Francisco, CA, USA
    We're developing a free vaccine to cure HIV and AIDs. Immunity Project is a non-profit initiative dedicated to developing an HIV vaccine. We hacked the HIV life cycle to develop a vaccine that gives you the same power as HIV controllers. With success in our clinical trials, our goal is to give our vaccine away to the world for free.
    health-tech
    biotech
  • Ovipost
    Ovipost (w2018)Active • 20 employees • LaBelle, FL 33935, USA
    Ovipost builds automated insect farms. Insects are the most efficient way to convert abundant, cheap byproducts into nutritionally dense protein. Today live insects are a $175m industry in the US, but the future of the industry is leveraging their excellent amino acid profiles and superior digestibility to replace fishmeal ($9.5B industry) and other expensive proteins in animal feeds. Led by co-founders Trina Chiasson (sold Infoactive to Tableau) and Teq Sassmannshaus (biotech hardware engineer), the Ovipost team has deep experience in hardware, software, and biology. 
    biotech
    climate
    food-tech
    agriculture
    climatetech
  • Nephrogen
    Nephrogen (s2020)Active • 1 employees • New York, NY, USA
    We're building curative gene therapies for kidney diseases. Our initial focus is on polycystic kidney disease (PKD), which affects 600,000 Americans and has no effective treatment or cure.
    gene-therapy
    crispr
    biotech
  • Equator Therapeutics
    Equator Therapeutics (w2020)Active • 2 employees • San Francisco, CA, USA
    We are developing a drug to increase metabolism and burn calories without exercise. Obesity and type 2 diabetes have reached epidemic proportions. There are 2.2B overweight people and 500M people with type 2 diabetes worldwide, and these numbers increase drastically every year. Existing drugs are not effective enough to reverse the trend. Our drug can solve this problem, because it addresses the root cause of metabolic disorders – the imbalance between caloric intake and expenditure. Our drug will target mitochondria – the powerhouse of the cell – to generate heat. This approach has been proven to fully reverse obesity and type 2 diabetes in animals. However, therapeutic application for humans was impossible, because mitochondrial heat production could only be induced by highly artificial methods with side effects. This changed after our recent breakthrough discovery of the protein that mitochondria naturally use to generate heat. We have developed a unique high-throughput drug discovery platform to identify compounds that selectively activate this target protein, without side effects. For decades people have wanted a drug that burns calories like exercise does. We are realizing this dream at Equator Therapeutics.
    biotech
    therapeutics
  • Future Fields
    Future Fields (s2020)Active • 30 employees • Edmonton, AB, Canada
    At Future Fields, we’re changing the world - one fruit fly at a time. We’ve developed a novel insect-based expression platform that allows us to make the world’s most scalable and sustainable recombinant proteins.
    biotech
    climate
    cultivated-meat
  • Kernal Biologics
    Kernal Biologics (s2020)Active • 20 employees • Cambridge, MA, USA
    Kernal Bio creates mRNA 2.0 therapies that instruct specific cells on how to make their own medicine. Kernal Bio encrypts mRNA’s “message” in a language that only cancer cells understand. These tumor-specific mRNA therapeutics allow precise targeting of cancer cells, without harming normal cells or tissues. They have recently been validated in preclinical tumor models, showing high efficacy and safety as well as durable adaptive immunity. With roots at MIT, Harvard and Biopharma, Kernal’s management team has deep expertise in mRNA therapeutics space. CEO Yusuf Erkul, M.D., M.B.A. is a successful drug hunter whose research at Merck enabled an FDA-approved drug for ovarian cancer. President, Burak Yilmaz, M.S., previously founded Sentegen, a thriving synthetic biology company which commercializes synthetic DNA, RNA, and diagnostic kits for genetic and infectious diseases. VP of BD, Matt Strout, M.D. Ph.D., M.B.A, is a business development executive who led more than $4.5B worth of BD deals at Alexion and AstraZeneca. VP of R&D Manfred is a leader in immuno-oncology, who was most recently Scientific Senior Director at Bristol-Myers Squibb (BMS).
    biotech
    genomics
  • Synvivia
    Synvivia (s2016)Active • 4 employees • Berkeley, CA, USA
    Synvivia applies chemical control over cell behavior. This allows us to optimize biomanufacturing of high-value biopharmaceutical products.
    artificial-intelligence
    synthetic-biology
    biotech
    manufacturing
    drug-discovery
  • Sigma Genetics
    Sigma Genetics (w2017)Active • 2 employees • Seattle, WA, USA
    Sigma Genetics develops devices that can deliver DNA, RNA, and other charged molecules into cells by using magnetic fields. When compared to conventional electroporation, this technique has several key advantages, which include: the absence of arcing, the ability to scale, and the benefit of being non-invasive for in vivo applications. This platform technology can be applied to a wide range of applications- cell therapies, cancer drug delivery, DNA vaccines, biopharma manufacturing, and cosmetics.
    biotech
    genomics
  • Helix Nanotechnologies
    Helix Nanotechnologies (w2017)Active • 16 employees • Boston, MA, USA
    Technology finds information and delivers physical products to us almost instantly. mRNA does the same for biology. At HelixNano, we see a world where treatments are cheap, progress is decentralized, and you can modify biology at the push of a button. By focusing on mRNA improvements from first principles, we’re getting there faster than we thought. Experiments that used to take months or years can be done in weeks and cost thousands instead of millions. The rate limiting step for our progress is now scientific curiosity. Rigid hierarchies and top-down decisions will miss the magic. Some of our most powerful technologies started out as side projects of junior team members. At HelixNano, every individual scientist can have a massive impact on the company's direction. And the more diverse our team, the faster we’ll find the really cool ideas. We've started rolling out some of our new tech — moving a COVID-19 vaccine candidate for the immunocompromised towards the clinic, and testing an intervention with massive environmental impact. But we’re scientists at heart, and team focus is solidly on the horizon.
    artificial-intelligence
    biotech
    genomics
    nanotechnology
  • iollo
    iollo (s2022)Active • 3 employees • San Francisco, CA, USA
    iollo is an at-home metabolomics test to extend your healthy lifespan. We measure more than 500 biomarkers in blood and use AI to automatically match you with dietary, behavioral, and therapeutic interventions.
    generative-ai
    health-tech
    biotech
    enterprise
    ai
  • Lucy Goods, Inc
    Lucy Goods, Inc (w2018)Active • 7 employees • Los Angeles, CA, USA
    If it isn’t bad enough that smokers don’t realize the scientific facts about nicotine, most non-tobacco nicotine products are poorly designed and unappealing to use. The leading gum is sold like a pharmaceutical drug, with flavoring and packaging to match. Vapes provide a cumbersome, over-the-top experience — with use as tightly restricted as cigarette smoking itself, but more juvenile, conspicuous, and highly addictive. People want, and deserve, a better way. Therefore, we want to deliver nicotine users a superior experience, and at the same time give them a way to transition out of feeling dependent. In a better society, people wouldn’t carry around the sensation that they’re stuck with an involuntary habit. Our mission isn’t to encourage nicotine use among people who haven’t started. Unlike certain vapes or other products, ours isn’t the sort coveted by underage users on social media. Our mission is to alleviate the harm related to tobacco — first and foremost, by switching people away from the most harmful products. So, at Lucy, we take an evidence based view of nicotine. Nicotine’s pleasurable properties make it an inevitable part of modern society. Therefore, minimizing harm in all nicotine products is key, in addition to giving people products and strategies for cessation. We feel that, as 1,300 people are dying of tobacco related illnesses every day in the US, the most important and immediate step toward a better society is giving nicotine consumers products they enjoy using that will cause less harm. Our first product is designed to appeal to smokers and encourage them to switch. And, looking ahead, we hope to secure approval in the future as a clinically proven smoking cessation aid, while continuing to participate in the FDA’s public hearings around how NRTs are best regulated. Our goals are simple: because harm reduction is a better strategy around nicotine delivery than abstinence or prohibition, we want to help improve public health — and reduce its costs — through a superior pure nicotine product.
    3d-printed-foods
    biotech
    e-commerce
  • C16 Biosciences
    C16 Biosciences (s2018)Active • 35 employees • New York, NY, USA
    C16 Biosciences is decarbonizing consumer products supply chains by producing next-generation ingredients. The company's biomanufacturing platform produces better performing, more sustainable alternatives to oils and fats, and their first product is an alternative to palm oil. The company owns and operates Palmless™ alternative fats and oils.
    biotech
    sustainability
    climate
  • Reverie Labs
    Reverie Labs (w2018)Active • 29 employees • Cambridge, MA, USA
    Reverie Labs is engineering next-generation, brain-penetrant cancer therapies.
    ai-powered-drug-discovery
    machine-learning
    biotech
  • CB Therapeutics
    CB Therapeutics (s2018)Active • 18 employees • San Diego, CA, USA
    CB Therapeutics is a synthetic biology company focused on bringing cannabinoid and tryptamine therapeutics to the clinic and commercial markets to treat depression, PTSD, opioid addiction, alcoholism, pain, and other mental health problems.
    cellular-agriculture
    biotech
  • Transcriptic
    Transcriptic (w2015)Active • 13 employees • Menlo Park, CA, USA
    Founded in 2012, Transcriptic has developed the first robotic cloud lab platform for on-demand life science research. It’s powered by the Transcriptic Common Lab Environment (TCLE) a scalable, digital infrastructure that integrates laboratory processes, instruments and IoT technologies into a single user interface. Researchers can carry out scalable, reproducible and rapid experimentation from anywhere in the world. Top ten pharmaceutical companies, as well as emerging biotech companies, are using the platform to gain more reproducibility and flexibility in the design and control of their experiments. By leveraging cloud-based technologies, users can access the power of a fully automated laboratory – whether in their own labs through an on-premise deployment of TCLE or through Transcriptic’s Bioassays services – all through a simple web-based interface. Transcriptic is transforming drug discovery and synthetic biology research by helping scientists focus on accelerating discoveries instead of labor-intensive bench work.
    robotics
    biotech
  • Valink Therapeutics
    Valink Therapeutics (w2021)Active • 12 employees • London, UK
    Valink Therapeutics develops next generation antibody-based therapeutics. We identify novel mechanism of action from known targets by incorporating multiple antibody modifications at once, rapidly and scalable generating complex drug candidates (bi-/multispecificity, multivalency and drug-conjugation in a single discovery process). Our research focus is on solid tumours poorly addressed by immunotherapy.
    biotech
    therapeutics
    drug-discovery
  • GEn1E Lifesciences (s2019)Active • Palo Alto, CA, USA
    GEn1E Lifesciences is a Clinical-stage, multi-target company with a unique AI platform. We develop novel, next-generation, immunomodulatory therapies for rare & inflammatory diseases with no effective treatments. Our team is supercharging the drug development cycle by applying AI to multiple-mechanism-of-action protein targets and their natural platform capabilities—creating novel therapeutics at an unprecedented pace. Our AI platform has enabled us to develop a purpose-built therapy for ARDS to reduce its $20 billion cost on society (just in the USA). GEn1E has built a rich pipeline of 21+ novel and selective immunomodulators and has plans to accelerate 2 additional devastating diseases (beyond their lead indication) to IND in the next 12 months. Our AI platform enables tremendous pace and capital efficiency as demonstrated by our progress in ~2 years with seed capital—a stark contrast to the typical spend of $100M+ and 7+ years exhibited in the pharmaceuticals / biotech industry. With ~90% of rare diseases having no therapeutic treatment at all, GEn1E is taking a giant swing that will hopefully bring life-saving therapies to the lives of patients in need. The team at GEn1E has decades of experience in drug development and machine learning. We graduated from YCombinator and Stanford-StartX in late 2019. We are based in Palo Alto, CA.
    artificial-intelligence
    biotech
    healthcare
    drug-discovery
  • Cofactor Genomics
    Cofactor Genomics (s2015)Active • 13 employees • St. Louis, MO, USA
    Cofactor uses RNA and Predictive Immune Modeling to build better biomarkers and improve patient outcomes. Led by Jarret Glasscock and a group of expert human genome scientists,Cofactor has built a new category of diagnostic technology powered by unique and powerful RNA data models built on terabytes of data. The team recently had their technology validation peer-reviewed by the organizations that set standards for diagnostic technology (CAP, AMP) and is publishing in the Journal of Molecular Diagnostics. In addition, the team made news when Cancer Physicians who sit on the committee for patient treatment guidelines (NCCN) presented a clinical study using Cofactor’s technology showing superiority in predicting the patients who will respond to immunotherapy. This initial application is an acute problem recognized widely in the rapidly developing immunotherapy industry and represents north of a billion dollar TAM. After a number of recent key milestones, the team is taking the technology more broadly to 50% of cancers diagnosed in the US. Current investors include Menlo Ventures, DCVC, and Ascension Ventures (this last investor representing the funding arm for 13 National U.S. Healthcare Systems).
    medical-devices
    biotech
    diagnostics
  • Altay Therapeutics (w2020)Active • 6 employees • San Carlos, CA, USA
    Altay develops small molecule drugs to treat chronic liver diseases like liver fibrosis and liver cancer. Our co-founder Dr. Osman Ozes, led the first drug development program for Esbriet (Pirfenidone), resulting in the first FDA approved therapy for lung fibrosis. Esbriet is now a $1 billion/year drug and has already made over $6 billion in revenue. With a team that has over 70+ years of small molecule drug development experience, we intend to do the same with chronic liver diseases, which affects over 20 million Americans and represents a market size of over $30 billion. We know we are well positioned for success because we have shown excellent pre-clinical mouse data in several liver fibrosis models using our novel small molecule. We demonstrate a reduction in fibrosis with our drug, but more significantly, we show a reversal in fibrotic tissue back to normal tissue. With our current developmental strategy, we hope to have a clinic-ready compound by the end of 2021 and be in phase I clinical trials by mid of 2022.
    ai-powered-drug-discovery
    biotech
    therapeutics
    drug-discovery
  • Isabl
    Isabl (w2020)Active • 5 employees • New York, NY, USA
    Isabl has developed software that can analyze the entire genome of cancer patients. Today, when people get cancer, they get a genetic test of their tumor that analyzes only a few possible mutations. With Isabl, you run the tumor through an Illumina sequencer and get the whole genome, then our software is able to analyze all the mutations. Our breakthrough technology provides unprecedented clarity into tumor biology to aid treatment planning. This opens up opportunities for precision diagnostics, disease surveillance and biomarker discovery.
    biotech
    diagnostics
  • Ochre Bio
    Ochre Bio (w2020)Active • 50 employees • Oxford, UK
    Ochre Bio is a biotechnology company developing RNA medicines for chronic liver diseases.
    biotech
    genomics
  • Nanograb
    Nanograb (s2023)Active • 3 employees • San Francisco, CA, USA
    Nanograb is a computational drug discovery company that uses AI to generate the best combination of binders to treat different diseases. Our product allows drugs to be targeted to very specific areas of the body.
    ai-powered-drug-discovery
    nanomedicine
    biotech
    drug-delivery
    therapeutics
  • HistoWiz (w2016)Active • 2 employees • Brooklyn, NY, USA
    HistoWiz is an innovative company dedicated to accelerating pathology-based research. HistoWiz provides fast, global access to digital whole-slide images, online collaboration tools, low-cost data management, and experimental pathology expertise. The web-based platform accelerates information exchange among medical scientists and research pathologists. HistoWiz's mission is to fight cancer cooperatively instead of individually by connecting scientists and pathologists for online collaboration. The HistoWiz advantage We help your lab minimize the cost of research and maximize research productivity by providing the most efficient service for scientists to analyze experimental pathology specimens. We believe that scientists should spend their time on results interpretation rather than repetitive tissue cutting. How does it work? HistoWiz accepts formalin-fixed specimens by mail for tissue processing services. To expedite delivery of results and to facilitate global collaboration, HistoWiz offers whole-slide imaging and pathology services, allowing researchers to remotely and instantly view high-magnification images of their specimens via a secure, cloud-based “virtual microscope” on any computer or mobile device without downloading any software or gigabyte-sized files.
    biotech
    ai
  • Olio Labs
    Olio Labs (s2023)Active • 2 employees
    Olio labs uses AI to develop combination therapeutics that consider the thousands of interacting proteins in your body rather than targeting just one or two. Their lead combinations target obesity and are more effective with fewer side effects than Ozempic, the fastest growing drug of all time. Their custom ML built from real-world expertise and cutting edge AI searches trillions of combinations to find the perfect one.
    artificial-intelligence
    biotech
    therapeutics
    drug-discovery
    biotechnology
  • Adventris Pharmaceuticals
    Adventris Pharmaceuticals (w2023)Active • 7 employees • Baltimore, MD, USA
    Adventris makes cancer vaccines. By teaching our body’s immune system to recognize and kill the drivers of cancer, we can eliminate the majority of all cancer deaths. A little more detail to understand our scientific approach: A normal cell turns into cancer when it develops a mutation that makes it grow aggressively. Surprisingly, a small number of these mutations account for the vast majority of cancer deaths. The immune system usually doesn’t recognize these mutations, but our technology platform enables us to train the immune system to recognize and attack these cancers. Our first product is a vaccine for the treatment of lung cancer that targets the KRAS mutation, the most common mutation in cancer, accounting for about 30% of all cancer deaths. In the long run, we envision a world where every adult receives our vaccines annually – preventing the majority of cancer deaths. Our team includes some of the leading cancer vaccine experts in the world including: our Chief Scientific Officer, Dr. Liz Jaffee (Chair of President Biden’s Cancer Advisory Panel) and our Chief Medical Officer, Dr. Mark Yarchoan (principal investigator of multiple cancer vaccine clinical trials). Our team is led by our Chief Executive Officer, Jen Herbach, who has more than a decade of biotech industry experience including with Amunix (the second largest oncology pre-clinical stage acquisition). If you are interested in learning more about our approach to treat and prevent cancer, please reach out to us at contact@adventrispharma.com
    biotech
    healthcare
    therapeutics
    drug-discovery
    oncology
  • Invitris
    Invitris (w2023)Active • 6 employees • Munich, Germany
    Invitris radically simplifies how we create novel biological drugs. Our patent-pending technology platform turns DNA into synthetic proteins and was recently featured in the Science magazine. It makes creating new drugs >10,000x more efficient at <100x lower costs of material. Our killer application is enabling the newest generation of synthetic bacteriophages to combat antibiotic-resistant infections, which are threatening to cause more deaths than all cancers combined.
    biotech
    nanotechnology
    drug-discovery
  • Arpeggio Bio
    Arpeggio Bio (s2019)Active • 20 employees • Boulder, CO, USA
    Arpeggio Bio is a pioneering pharmaceutical company that develops drugs targeting transcription factors using AI and high-throughput RNA-sequencing. With $20M in venture funding, we've targeted "undruggable" proteins like NRF2, TEAD, and GPX4 where our lead program is rapidly progressing towards a DC for the treatment of IO-resistant melanoma. With partnerships with J&J and FORMA, we've validated our platform in rare disease and inflammation with a significant Phase I success.
    biotech
    genomics
    drug-discovery
  • Modulari-T
    Modulari-T (w2023)Active • 4 employees • Montreal, QC, Canada
    Cell and gene therapy promises to one day cure any disease; Modulari-T’s Platform produces the tools to fulfill that promise. Modulari-T has designed a new family of synthetic genes that can reprogram cells to better sense their environment and modify their behavior accordingly. This can be used to engineer immune cells to efficiently recognize and kill cancer cells or to create stem cells able to regenerate any tissue. Modulari-T looks to expand its technology to reach every area of cell therapy and become the platform of reference for cell engineering.
    gene-therapy
    cell-therapy
    synthetic-biology
    biotech
    oncology
  • Pando Bioscience
    Pando Bioscience (w2023)Active • 5 employees • Boston, MA, USA
    Pando is an AI-driven synthetic biology company revolutionizing enzyme engineering for the pharmaceutical industry. Our ultra-high-throughput screening platform screens 1000-fold more enzymes 75% faster and 80% cheaper than traditional methods. This empowers our generative AI to efficiently optimize enzymes across multiple properties, delivering high-performing, tailored enzymes that reduce costs and enhance efficiency.
    ai-powered-drug-discovery
    generative-ai
    synthetic-biology
    biotech
    diagnostics
  • Reshape Biotech
    Reshape Biotech (w2021)Active • 40 employees • Copenhagen, Denmark
    Reshape Biotech builds lab robots that automate the everyday tasks of microbiologists, from filling plates to analyzing images. Other companies try to sell “one lab robot that does everything”. But those robots become so complicated that they sit unused on the shelf. We build one robot for each function, which makes them easy to use.
    robotics
    biotech
  • Talus Bio
    Talus Bio (s2021)Active • 16 employees • Seattle, WA, USA
    We have built a platform that enables drug discovery and development for previously undruggable genome regulators ("the regulome"). We accomplish this by moving drug discovery out of artificial systems where regulome proteins fail to function properly, and back into live human cells. Our technology combines innovations in automated cell processing, next-gen proteomics, and advanced data analytics to measure a drug's effect on the entire regulome in one experiment.
    biotech
    genomics
    drug-discovery
  • Mindstate Design Labs
    Mindstate Design Labs (s2021)Active • 7 employees • San Francisco, CA, USA
    Developing the next generation of psychedelic therapeutics for mental health indications. We design novel altered states of consciousness using machine learning, human experiential data, and molecular pharmacology.
    artificial-intelligence
    machine-learning
    mental-health-tech
    biotech
    therapeutics
  • Catena Biosciences
    Catena Biosciences (s2021)Active • 7 employees • Berkeley, CA, USA
    Catena’s technology lets us attach any two proteins together using an enzyme and the native amino acids tyrosine and cysteine within target proteins. It is a true platform technology because it enables the joining of any two soluble proteins together with minimal engineering and without restrictions due to protein size or complexity. Our work has already been used to modify cancer specific antibodies, CRISPR proteins and even cell surfaces. Our ability to produce modular protein therapeutics in a fraction of the time allows for true library creation across the therapeutics spectrum from oncology, vaccines, inflammatory disease and beyond.
    biotech
    therapeutics
  • Parallel Bio
    Parallel Bio (s2021)Active • 9 employees • Cambridge, MA, USA
    Parallel Bio created a human 'immune system in a dish' to discover drugs and immunotherapies more likely to work in patients. Our platform has all of the same elements as a human immune system, meaning you can test drugs and vaccines as if you were testing them in actual patients from the start. The biggest reason why 95% of new drugs fail is that they were tested in mice - but with our human platform, pharma companies will know which drugs will successfully treat patients, speeding up the process and reducing the cost. To date our platform has successfully been used to test 12 drugs, and vaccines against 8 different diseases. The company is founded by Robert DiFazio, a former Stanford R&D director with a PhD in immunology, and Juliana Hilliard, a former System1 Biosciences R&D lead with an MSc in bioengineering, both of whom have led drug discovery programs for years.
    ai-powered-drug-discovery
    biotech
  • BLUUMBIO
    BLUUMBIO (s2021)Active • 4 employees • Berkeley, CA, USA
    Our mission -To ensure current and future generations have access to clean soil, water & air. -To protect and restore earth's beautiful and diverse ecosystems. -To undo the harm of industrial activity on the planet and ensure future industrial activities are more sustainable. Our research -We develop new bio-based solutions that break down and remove toxic chemicals from the environment.  We also develop bioreactor based solutions which remove toxins from industrial production pipelines, ensuring contaminants are never released into the environment. -To do this, we've partnered with Nature. Specifically, we have harnessed the power of one of Nature's smallest but most powerful technologies: enzymes. Enzymes are everywhere. They break down the food in your stomach, remove dirt from your clothes, and make our beer. At BluumBio, we look for enzymes found in bacteria, algae, plants and other living organisms that naturally degrade toxic chemicals. We then make these enzymes work better in the lab and come up with develop new applications for these technologies.
    biotech
    sustainability
  • Yemaachi Biotechnology
    Yemaachi Biotechnology (s2021)Active • 16 employees • Accra, Ghana
    Yemaachi Biotech is diversifying and expanding access to precision cancer diagnostics and therapeutics by collecting and sequencing samples from all across Africa, which is the most genetically diverse population on the planet. We then use this data to either optimize existing diagnostic tests, or help other companies discover new ones. With our research activities based in Africa, we are able to leverage access to the most genetically diverse population on the planet to build a first-of-its-kind clinical and molecular knowledgebase on cancer among African people.
    biotech
    diagnostics
    therapeutics
  • Argon AI, Inc.
    Argon AI, Inc. (w2024)Active • 2 employees • 79 Buena Vista Terrace, San Francisco, CA 94117, USA
    Argon AI is a platform where biopharma and life sciences professionals can execute complex and data driven workflows using natural language. We help professionals get thorough answers to questions about clinical trials, existing treatments, healthcare landscape, and the competitive market in minutes rather than months. Prior to starting Argon, Samy was responsible for Flatiron Health’s (Roche) first data analytics project which eventually led to the start of the Flatiron Services business unit. There, he saw first-hand the heavily manual process that biopharma companies struggle through to get the insights they need to drive forward their drug development programs. He also helped close over $6M+ in ARR and is an expert in enterprise pharma sales. Cyrus previously led engineering teams and built 0 to 1 across pre-seed and unicorn startups, managed mission-critical trade generation systems at Bridgewater, and held AI advisory roles at various startups. Cyrus has a duel degree in EE and CS from USC. Breakthroughs in AI present an opportunity to reinvent biopharma and life science workflows to reduce the time and cost of bringing treatments to patients where delays in bringing a drug to market can cost a pharma company $3M / day.
    b2b
    biotech
    therapeutics
    enterprise-software
    ai-assistant
  • Kiwi Biosciences
    Kiwi Biosciences (s2021)Active • 8 employees • Boston, MA, USA
    Kiwi Biosciences can help 18M Americans suffering from Irritable Bowel Syndrome (IBS) enjoy a normal meal without running to the bathroom two hours later. We develop novel, patent-pending enzymes that break down common digestive triggers in food.
    biotech
    food-tech
  • Sensible Biotechnologies
    Sensible Biotechnologies (s2021)Active • 17 employees • Oxford, UK
    The future of mRNA therapeutics is hampered by manufacturing challenges and unless solved, its exciting potential may never be realised. Sensible enables the next generation of mRNA medicines by turning living cells into factories producing abundant, highly stable and non-immunogenic mRNA in a scalable and cost-effective way.
    synthetic-biology
    biotech
    manufacturing
    therapeutics
    biotechnology
  • Output Biosciences
    Output Biosciences (s2021)Active • 4 employees • New York, NY, USA
    Output Biosciences is the world’s first preventative therapeutics company that extends human healthspan by combating chronic disease.
    ai-powered-drug-discovery
    generative-ai
    biotech
  • Medium Biosciences
    Medium Biosciences (s2021)Active • 6 employees • Boston, MA, USA
    We build AI models helping our customers create novel, high performing biomolecules faster. Our AI models simulate the biophysical properties of biomolecules and identify the most promising ones to be tested in the lab.
    ai-powered-drug-discovery
    artificial-intelligence
    biotech
    climate
  • Yoneda Labs
    Yoneda Labs (w2024)Active • 3 employees • San Francisco, CA, USA
    Yoneda Labs provides software to help chemists optimise reactions. When chemists make a drug or a material, we help them figure out the best reaction parameters such as temperature, concentration and catalyst. When Jan was working at chemical labs, he experienced the struggle of spending weeks guessing reaction conditions. We then started experimenting with ML to speed up the process. Now, as a team of three friends from the University of Cambridge, we’ve spent the last month combining our domain expertise in Computer Science, Machine Learning and Chemistry to develop state of the art models for reaction optimisation. Although ML is becoming well established in other fields, current chemical models generalise poorly and require lots of programming experience. We make our models easily accessible to chemists in the lab. Finding the right conditions quickly allows pharmaceutical companies to test more drugs, and finding better optima makes manufacturing process cheaper and more environmentally friendly.
    artificial-intelligence
    b2b
    biotech
    design-tools
    ai
  • SynsoryBio
    SynsoryBio (w2024)Active • 2 employees • Cambridge, MA, USA
    SynsoryBio is creating next generation, protein therapeutics that sense where they are in the body and only activate at diseased tissue. This technology platform has the potential to expand the therapeutic window of highly potent drugs and apply to many diseases such as cancer and autoimmune disorders.
    synthetic-biology
    biotech
    therapeutics
    oncology
  • Keylika
    Keylika (s2022)Active • 1 employees • Walnut Creek, CA, USA
    Keylika is an early stage biopharma startup developing metal-based drugs using a platform synthesis technology to treat unmet medical needs. We then administer these drugs using proven delivery technologies to effect the best clinical outcomes. Our first product is a small molecule iron drug (new molecular entity) delivered by a wearable skin patch to treat Iron Deficiency Anemia (IDA), with significantly higher safety, efficacy and tolerability over existing treatments. This is poised to be a best-in-class, potentially breakthrough therapy for treating iron deficiency without any GI side-effects (eg. nausea, constipation, diarrhoea, etc.) typically associated with oral iron supplements, and without the risks, costs and side-effects associated with IV iron infusions. When approved, Keylika’s proprietary transdermal iron will be the world's first prescription iron patch. Iron deficiency is a hugely understated problem affecting about 1.6 billion people worldwide and more than 30 million in the US alone, translating to a $17B US market.
    medical-devices
    biotech
    nanotechnology
    therapeutics
    drug-discovery
  • Engage Bio
    Engage Bio (w2022)Active • 5 employees • Santa Clara, CA, USA
    Engage Bio is developing mRNA immunotherapies to defeat cancer. Our founders have deep experience in immunotherapy development, including four drugs in the clinic, and in building mRNA therapeutics platforms. Our approach is to provide cancer cells with instructions to make and gradually release our drugs within solid tumors. This local therapy allows us to eliminate tumors while sparing healthy distant tissues.
    synthetic-biology
    biotech
    healthcare
    therapeutics
    drug-discovery
  • Brown Foods
    Brown Foods (w2022)Active • 4 employees • Boston, MA, USA
    Brown Foods is a Stanford, Rice University and IIT Delhi alumni venture building the next-generation of food products. They are creating UnReal Milk- lab based, clean milk - extremely sustainable 'real milk' but made without any cows. Unlike any other option in the USD 22 billion dairy alternatives market today, it will be exactly similar to cow’s milk in terms of nutritional profile, taste, texture and could also be processed into butter, cheese and ice creams. They envision to disrupt the USD 700 billion conventional dairy market by giving the world its 1st 'cow free' real milk option, reducing the carbon footprint of milk by over 90% while being completely cruelty-free.
    cellular-agriculture
    biotech
    climate
    food-tech
  • HypaHub
    HypaHub (w2022)Active • 6 employees • Sunnyvale, CA, USA
    HypaHub is a Cloud-Based Bioinformatics and AI Platform. It is the first HIPAA-compliant Bioinformatics SaaS that runs natively on users' clouds, providing both operation- and price-transparency. Our product is a one-stop shop to access complex technologies designed for scientists building data applications or performing data analytics to extract insights. It automates the creation and manages the operation of computing resources, eliminating the need for enterprises to set up and maintain a high-end R&D cloud infrastructure.
    machine-learning
    biotech
    analytics
  • Alixia
    Alixia (w2022)Active • 2 employees • San Francisco, CA, USA
    Our compounds disrupt the metabolic and inflammatory triggers in both cancer and quasi-cancerous cells in the tumor microenvironment. By impacting multiple cell types, we are enabling effective, lasting cancer treatments.
    biotech
    therapeutics
    drug-discovery
    oncology
    biotechnology
  • Alga Biosciences
    Alga Biosciences (w2022)Active • 5 employees • Berkeley, CA, USA
    Alga Biosciences is a fast-moving startup focused on transforming the agricultural industry. Our mission is to make an immediate, dramatic impact on global methane emissions produced by enteric fermentation in partnership with the cattle industry. We believe in leveraging biology to tackle the world’s biggest problems.
    biotech
    climate
    agriculture
  • Torpedo Therapeutics
    Torpedo Therapeutics (w2022)Active • 5 employees • Boston, MA, USA
    We are building high-precision implantable neuromodulation devices that can sense and stimulate neural activity in the brain with the goal of transforming the efficacy and adoption of deep brain stimulation (DBS), an existing FDA-approved therapy used to treat Parkinson’s, essential tremor and epilepsy.
    neurotechnology
    medical-devices
    biotech
  • Andson Biotech
    Andson Biotech (w2022)Active • 4 employees • Atlanta, GA, USA
    Andson Biotech helps pharmaceutical companies measure difficult to detect chemicals that they need to measure while developing and manufacturing drugs like cell-therapies or biologics. Drug companies want to use our technologies to get fast and accurate chemical measurements they do thousands of times per day for drug development and quality control.
    gene-therapy
    hard-tech
    biotech
    healthcare
    therapeutics
  • Fortuna Genomics
    Fortuna Genomics (w2022)Active • 1 employees • Cambridge, MA, USA
    Fortuna Genomics employs methods from revolutionary genomics studies to non-invasively assess embryo traits, enabling parents to optimize their children's innate qualities without the need for gene editing. Through comprehensive genetic screening and forecasting, it empowers families to make informed decisions, optimizing their child’s well-being and capabilities from conception. With the convergence of advancements in genomic technologies, association studies, and sequencing efficiency, we are at a unique inflection point where such services can become widely accessible and impactful. Accurately predicting complex traits from genetic markers involves sophisticated models that must account for the interplay between countless biological and statistical factors. Our team is well-equipped to tackle this problem and make every parent's dream a reality by allowing them to give their children the best possible start in life.
    fertility-tech
    biotech
    genomics
  • Origami Therapeutics, Inc.
    Origami Therapeutics, Inc. (w2022)Active • 4 employees • San Diego, CA, USA
    Origami Therapeutics, Inc. is a biotech company developing novel protein degraders with potential to delay or halt disease progression by eliminating toxic proteins from the body. Our drug discovery platform leverages our proprietary human disease models developed to select the small molecules with the best chance of clinical success. Our first indication is Huntington’s disease, a debilitating, progressive and ultimately fatal disorder caused by a genetic mutation. We have already identified small molecules that reduce the toxic mutated protein, suppress mutant protein-induced toxicities in human disease neurons and get into the brain. We anticipate that this approach will be broadly applicable to traditionally “undruggable” targets in other neurological diseases.
    biotech
    therapeutics
    drug-discovery
  • Cisterna Biologics
    Cisterna Biologics (s2022)Active • 2 employees • San Diego, CA, USA
    Founded in 2022 and based in San Diego, California, Cisterna Biologics is a technology company. It aims to solve some of the challenges currently facing the biotech industry to develop mRNA-based therapeutics – quality, quantity, longevity and cost of mRNA. As mRNA technology matures, it becomes imperative that these issues are solved so we can fully explore mRNA's endless possibilities as a therapeutic. Cisterna uses proprietary technologies to either remove a contaminant at its source or replace the source itself. For example, to remove double-stranded RNA (dsRNA), we use ribozymes - molecular scissors - to precisely cut the mRNA at its 3’ end. This assures not only 3’ homogeneity, but also eliminates dsRNA, which are primarily produced due to self-templated additions at the 3’ end. Utilizing a PCR-like system to amplify the DNA template in large quantities eliminates the requirement for plasmid enrichment in bacteria, the prime source of endotoxin contamination. These are just a few examples of Cisterna’s powerful technologies being used to achieve our goal of 10x higher quality mRNA for therapeutic application.
    synthetic-biology
    biotech
    therapeutics
  • Serinus Biosciences
    Serinus Biosciences (s2022)Active • 6 employees • New York, NY, USA
    Serinus Biosciences is tackling one of the toughest problems in cancer treatment: creating combination therapies to override treatment resistance. We leverage cutting edge technology to design a fully explainable AI platform primed with decades of system biology knowledge. Uniquely powered for biological inference, our AI engine uncovers how cancer cells evolve treatment resistance and identifies molecules to overcome resistance escape routes. We design combinations that are safer, more effective, and can get to patients quickly. Founded by MIT PhDs and supported by a scientific advisory board of top academics from the Broad Institute, Dana-Farber, and UCSD, Serinus is powered by Y Combinator and other top investors to revolutionize precision medicine.
    biotech
    therapeutics
    oncology
  • Signatur Biosciences
    Signatur Biosciences (s2022)Active • 5 employees • London, UK
    We make precision diagnostics more accessible, starting with breast cancer prognosis. Current tests that guide the use of therapy are really slow and expensive because they need to be run in complex centralized facilities. Our tests are designed to be easily run by local hospital labs, reducing turnaround time from over three weeks to a few days and for half the price.
    biotech
    healthcare
    diagnostics
  • ALT TEX
    ALT TEX (s2022)Active • 10 employees • Toronto, ON, Canada
    ALT TEX is a Toronto-based biomaterials startup that has developed the world’s first biodegradable and carbon neutral fabric, engineered from the world’s largest landfill contributor - food waste. Polyester alone makes up 60% of the $2.5 trillion fashion industry and is the biggest blocker preventing brands from meeting sustainability mandates. The patent-pending ALT TEX fermentation technology creates a polyester alternative that works with the existing infrastructure to supply a sustainable, high performance and cost competitive polyester replacement to fashion brands, at scale. The product solves key problems for fashion brands, consumers, and the environment: (1) Fashion brands: ALT TEX sells fabric to fashion brands, allowing them to differentiate via sustainable options (sustainable fashion growing 11% CAGR) and hit sustainability targets, without sacrificing performance or changing their current supply chain. (2) Consumer: The ALT TEX fabric is projected to be half the price vs. other specialized sustainable alternatives (due to low-cost input and scalability), meaning greater accessibility. (3) Environment: A single shirt produced with ALT TEX fabric can divert 1 kg of food waste from landfills, 9 kg of carbon emissions from the air, and 4 g of micro-plastics from our waterways. Co-founders Myra and Avneet have worked together managing teams and projects for six years, with backgrounds in serial entrepreneurship, corporate sales at Fortune 500 companies, textile manufacturing and biochemistry. To date, ALT TEX has created their first fabric prototype that’s 70% stronger than cotton, secured $1M in LOIs and raised $2.3M.
    carbon-capture-and-removal
    bioplastic
    biotech
    climate
    food-tech
  • Lamin
    Lamin (s2022)Active • 4 employees • Munich, Germany
    Manage data & analyses with an open-source Python framework. Collaborate across dry and wetlab in a distributed data hub. Get started on your laptop and deploy anywhere.
    developer-tools
    machine-learning
    biotech
    open-source
    data-engineering
  • ReleviumBio
    ReleviumBio (s2022)Active • 4 employees • Galway, Ireland
    ReleviumBio is developing an injectable gel for knee osteoarthritis. Approximately half the population will be diagnosed with this pain and progressive disease. Right now, patients have to undergo not only repeat injections to control their pain, but also have to take strong oral medications. Because the disease is progressive and only gets worse over time, many patients end up on highly addictive, high-dose opioids. To date, we have secured $3.7 million in non dilutive funding and completed preclinical testing. We demonstrated that our drug is safe, selectively blocks nerves that transmit pain, and provides pain relief that lasts four times as long. My co-founder and I are Chemists with PhDs in Biomedical Engineering and we have an experienced leadership team already in place. Insurance currently pays $770 per six-monthly treatment for knee osteoarthritis. With 5 million patients in the US, this represents a $7.7 Bn market opportunity. This platform biotherapeutic can also be used to treat other joints affects by osteoarthritis such as the hip and ankle, where the same problems exist in treatment care.
    medical-devices
    biotech
    healthcare
    therapeutics
    drug-discovery